Factors Influencing Outcome and Incidence of Late Complications in Children who Underwent Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathy

REFERENCES

• Di Bartolomeo P, Santarone S, Di Bartolomeo E, Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol. 2008;83:528–530.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Rovo A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. Hematology Am Soc Hematol Educ Prog. 2008;2008:125–133.
   Google Scholar
• Lee JW, Kang HJ, Kim EK, Effect of iron overload and iron-chelation therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2009;44:793–797.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous B-thalassemia. New Engl J Med. 1994;331:574–578.
   PubMed Web of Science ®Google Scholar
• Shalet SM, Didi M, Oglivy-Stuart Al, Growth and endocrine function after bone marrow transplantation. Clin Endocrinol. 1995;42:333–339.
   Google Scholar
• Lucarelli G, Galimberi M, Polchi P, Bone marrow transplantation in patients with thalassemia. N England J Med. 1990;322:417–421.
   PubMed Web of Science ®Google Scholar
• Michel G, Socie G, Gebhard F, Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total body irradiation–a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 1997;15:2238–2246.
   PubMed Web of Science ®Google Scholar
• Sodani P, Gaziev D, Polchi P, New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104:1201–1203.
   PubMed Web of Science ®Google Scholar
• Gaziev J, Sodani P, Lucarelli G, Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42:397–404.
   PubMed Web of Science ®Google Scholar
• Shalitin S, Phillip M, Stein J, Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 2006;37:1109–1117.
   PubMed Web of Science ®Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Complications of beta-thalassemia major in North America. Blood. 2004;104:34–39.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Arora M, Nagaraj S, Witte J, New classification of chronic GVHD: added clarity from the consensusdiagnoses. Bone Marrow Transplant. 2009;43:149–153.
   PubMed Web of Science ®Google Scholar
• Kalhs P, Schwarzinger I, Anderson G, A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelognous leukemia. Blood. 1995;86:2028–2032.
   Google Scholar
• Mathews V, George B, Lakshmi KM, Impact of pretransplant splenectomy on patients with B-thalassemia major undergoing a matched-related allogeneic stem cell transplantation. Pediatr Transplant. 2009;13:171–176.
   Google Scholar
• Michallet M, Corront B, Bosson JL, Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients. Bone Marrow Transplant. 1991;8:7–13.
   Google Scholar
• Gaziev J, Sodani P, Polchi P, Bone marrow transplantation in adults with thalassemia. Treatment and long term follow up. Ann N Y Acad Sci. 2005;1054:196–205.
   PubMed Web of Science ®Google Scholar
• Raiola G, Galati MC, De Sanctis V, Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab. 2003;16(Suppl 2):259–266.
   Google Scholar
• Gaziev J, Galimberti M, Giardini C, Growth in children after bone marrow transplantation for thalassemia. Bone Marrow Transplant. 1993;12:100–101.
   PubMedGoogle Scholar
• Li CK, Chik KW, Wong GW, Growth and endocrine function following bone marrow transplantation for thalassemia major. Pediatr Hematol Oncol. 2004;5:411–419.
   Google Scholar
• Bakker B, Oostdijk W, Bresters D, Disturbances of growth and endocrine function after busulphan-based conditioning for hematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 2004;33:1049–1056.
   Google Scholar
• Ghany AM, Tutschka PJ, McGhee RB Jr, Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy. Transplantation. 1991;52:310–315.
   PubMedGoogle Scholar
• Patchell RA. Neurological complications of organ transplantation. Ann Neurol. 1994;36:688–703.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Gratwohl A, Egger T, Cataract formation after bone marrow transplantation. Ann Intern Med. 1993;119:1175–1180.
   PubMed Web of Science ®Google Scholar
• Mieler WF, Kivlin JD. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology. 1999;106:1564–1570.
   Google Scholar
• Tichelli A, Duell T, Weiss M, Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European group or blood and marrow transplantation (EBMT) working party on late effects. Bone Marrow Transplant. 1996:17:1105–1111.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassemia. Br J Hematol. 2004;127:127–139.
   PubMed Web of Science ®Google Scholar
• Stern JM, Sullivan KM, Ott SM, Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant. 2001;7:257–264.
   PubMed Web of Science ®Google Scholar
• Socie G, Selimi F, Sedel L, Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Hematol. 1994;86:624–628.
   PubMed Web of Science ®Google Scholar
• Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 28;425–425.
   PubMed Web of Science ®Google Scholar
• Leung W, Ahn H, Rose SR, Aprospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore). 2007;86:215–224.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Lipsanen-Nyman M, Tiitinen A, Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. J Pediatr Hematol Oncol. 2007;8:29529–29534.
   Google Scholar
• Modell B, Khan M, Darlison M. Survival in beta-thalassemia major in the UK: data from the UK thalassemia register. Lancet. 2000;355:2051–2052.
   PubMed Web of Science ®Google Scholar
• Bashey A, Owen I, Bashey A, Late onset immune pancytopenia following bone marrow transplantation. Brit J Hematol. 1991;78:268–274.
   PubMed Web of Science ®Google Scholar
• Hartert A, Willenbacher W, Gunzelmann S, Successful treatment of thrombocytopenia and hemolytic anemia with IvIG in a patient with lupus-like syndrome after mismatched related PBSCT. Bone Marrow Transplant. 2001;27:337–340.
   Google Scholar